When we describe our target selection to researchers outside the longevity field, we get two types of reactions. Some people immediately engage with Klotho and FOXO3 as familiar signaling nodes they have encountered in pathway diagrams. Others want to know: are these real targets or longevity-research fashion? It is a fair question. The longevity field has seen targets cycle in and out of enthusiasm — telomerase, sirtuins, NAD+ — and the clinical translation record is not strong. So it is worth being precise about what the evidence actually says for Klotho and FOXO3, and where the line is between what's been demonstrated and what we are hypothesizing.
Klotho: From Kidney Gene to Systemic Aging Regulator
Alpha-Klotho was identified in 1997 by Kuro-o and colleagues in a mouse knockout study — mice lacking the Klotho gene aged rapidly, developing phenotypes resembling human aging including osteoporosis, atherosclerosis, skin atrophy, and shortened lifespan. The gene was named after one of the Greek Fates (Clotho, who spins the thread of life). The nomenclature has stuck; the biology has become considerably more complex.
Alpha-Klotho is primarily expressed in the kidney distal convoluted tubule, with secondary expression in the choroid plexus of the brain and parathyroid gland. It exists in two forms: a membrane-bound form that functions as a co-receptor for FGF23, and a soluble form (shed Klotho) that circulates in blood, urine, and cerebrospinal fluid. These two forms have distinct signaling mechanisms, which is important for understanding what mRNA-delivered Klotho would actually do.
Membrane Klotho and FGF23 Signaling
Membrane-bound alpha-Klotho forms a binary complex with FGF receptor 1 (FGFR1c) that dramatically increases the receptor's affinity for FGF23 — a phosphaturic hormone produced by osteocytes. This Klotho-FGFR1c-FGF23 signaling axis regulates phosphate homeostasis, suppresses the renal 1-alpha-hydroxylase that activates vitamin D, and inhibits PTH secretion. In chronic kidney disease, Klotho expression falls before serum Klotho drops measurably, and the dysregulation of this axis contributes to the secondary hyperparathyroidism and bone disease of CKD. This is well-established clinical physiology.
The relevance to aging is that Klotho expression declines with age in the kidney and choroid plexus, and that low serum Klotho levels in elderly populations are associated (epidemiologically, not causally proven) with higher cardiovascular mortality, cognitive decline, and reduced physical function. A large cross-sectional analysis from NHANES data showed that serum Klotho was lower in people with metabolic syndrome, higher CRP, and lower physical activity — but cross-sectional associations cannot establish that restoring Klotho levels would reverse these conditions.
Soluble Klotho: Anti-Aging Hormone or Biomarker?
Soluble Klotho — produced by ectodomain shedding of membrane Klotho by ADAM10 and ADAM17 metalloprotease activity — has been reported to have independent anti-aging signaling through several mechanisms. It inhibits Wnt and insulin/IGF-1 signaling, it modulates ion channel activity (TRPC1 and TRPV5), and in neuronal cell culture models it has neuroprotective effects against amyloid-beta-induced toxicity. Injecting recombinant soluble Klotho into aged mice improves cognitive performance in several published studies (notably work from Dubal and colleagues at UCSF).
The translational caveats are significant. Recombinant protein injection in rodents is a long distance from systemic upregulation of endogenous Klotho or delivery of mRNA encoding Klotho to a human patient. The Wnt inhibition property of soluble Klotho is particularly relevant for safety: Wnt signaling is essential for intestinal stem cell maintenance, bone homeostasis, and other tissue renewal processes. Chronically elevated soluble Klotho that broadly suppresses Wnt could have adverse effects in tissues where Wnt activity is needed. This is precisely the dose-response non-linearity problem we described in our mRNA sequence design article — there is a therapeutic window for Klotho upregulation, but we do not know precisely where it is.
We are targeting Klotho as an mRNA candidate because the genetics, the biology, and the rodent data collectively point to it as a credible intervention point. We are not claiming that delivering Klotho mRNA will improve human aging outcomes — that is a hypothesis requiring clinical data to test.
FOXO3: Genetics First, Then Biology
FOXO3 entered the longevity field through human genetics before the biology was fully understood. Multiple independent genome-wide association studies in long-lived human populations identified variants in the FOXO3 locus as associated with exceptional longevity. The most replicated finding comes from work by Willcox, Poulain, and colleagues in the Hawaii Lifespan Study and the CEPH cohort — specific SNPs in FOXO3 (notably rs2802292 in an intronic region) are enriched in centenarians compared to controls in multiple ethnic backgrounds. The association is among the most robustly replicated findings in human longevity genetics, appearing in Japanese, German, Italian, American, and Danish cohorts.
What the genetics does not immediately tell you is whether these variants increase FOXO3 expression, alter its regulation, or affect something else in the locus. There is evidence from reporter assays that the longevity-associated SNPs fall in regulatory regions that affect FOXO3 transcription in response to insulin/IGF-1 signaling, and that individuals carrying longevity-associated alleles have modestly higher FOXO3 levels in some tissue contexts. But the effect sizes are small and the functional data is not definitive.
FOXO3 as a Transcription Factor: What It Controls
FOXO3 (Forkhead Box O3) is a transcription factor that is phosphorylated and exported from the nucleus in response to insulin and IGF-1 signaling via AKT kinase. When PI3K-AKT signaling is low — as it is during caloric restriction, low insulin states, or stress — FOXO3 translocates to the nucleus and activates a broad transcriptional program. The targets include:
- Autophagy genes (including ULK1/ATG13, and components of the lysosomal biogenesis program via TFEB interaction)
- Reactive oxygen species scavenging genes (MnSOD/SOD2, catalase)
- DNA repair genes (GADD45 family members)
- Pro-apoptotic genes (BIM, FasL) in specific cellular contexts
- Cell cycle arrest genes (p27/CDKN1B)
The autophagy regulation is particularly relevant for neurodegeneration. Accumulation of protein aggregates — alpha-synuclein in Parkinson's, tau in Alzheimer's, TDP-43 in ALS — is partly a consequence of reduced autophagic clearance in aging neurons. A FOXO3-driven transcriptional program that upregulates autophagy flux should, in principle, improve the clearance of these aggregates. "In principle" is doing real work in that sentence — the in vitro and rodent data are supportive, but the translation to human neurodegenerative disease is not established.
The Context-Dependence Problem
FOXO3 presents a sharper context-dependence problem than Klotho. The same transcriptional program that promotes survival and autophagy in neurons can promote apoptosis in other cell types, depending on which co-factors are present and what the cellular stress context is. FOXO transcription factors, including FOXO3, were originally identified as tumor suppressors — their activity suppresses cell proliferation, which is beneficial in post-mitotic neurons but can impair tissue regeneration in proliferative compartments.
This means that systemic upregulation of FOXO3 via mRNA is not straightforwardly safe. A strategy that increases FOXO3 expression in all tissues simultaneously might reduce tumor suppression in some contexts while benefiting neuronal proteostasis in others. The cell-type-specific delivery problem — getting mRNA specifically to neurons rather than to liver or gut epithelium — is therefore not just a targeting challenge but a safety requirement for FOXO3. This is one reason our CNS delivery work is tightly coupled to the FOXO3 program rather than being a generic platform problem we can solve separately.
What Upregulation Could Theoretically Achieve
If we are successful in delivering mRNA encoding Klotho or FOXO3 to the relevant cell populations at physiologically meaningful levels, and if the safety constraints can be satisfied, the theoretical outcomes are worth articulating.
For Klotho in the choroid plexus and kidney: restoration of circulating soluble Klotho to levels seen in younger adults, which might attenuate the age-related decline in neuroprotective FGF23/FGFR1c signaling, reduce oxidative stress in brain vasculature, and potentially improve resilience against neuroinflammatory insults. The mechanistic plausibility is reasonable. The magnitude of effect in humans is unknown.
For FOXO3 in neurons: upregulation of autophagic clearance of protein aggregates, improved resistance to oxidative stress, and a transcriptional state resembling the "longevity program" seen in caloric restriction and IGF-1 signaling reduction. This could plausibly slow the accumulation of aggregate burden that drives neurodegeneration over decades. The effect would be more relevant as a preventive or early-stage intervention than as a treatment for patients who already have substantial neuronal loss.
We want to be precise about the boundary here. The epidemiological genetics of FOXO3 longevity variants is robust human data. The in vitro and rodent biology of FOXO3's autophagy and stress-response programs is solid. What is not established is whether delivering FOXO3 mRNA to human neurons at a specific dose will produce the intended transcriptional response without activating the pro-apoptotic arm, in the specific disease context of human age-related neurodegeneration. That is the core scientific question, and it requires animal model data in neurodegeneration-relevant model systems before human studies are conceivable.
How These Targets Emerged from Our Pipeline
Klotho and FOXO3 are not hypotheses we began with — they are targets that surfaced when we ran our comparative genomics pipeline and then cross-referenced with human longevity genetics. Klotho pathway components show positive selection signatures in naked mole rat sequence data and the choroid plexus expression profile maps cleanly onto the brain aging biology we care about. FOXO3 appears as a hit when you look at regulatory region conservation across long-lived species alongside the human centenarian GWAS data.
The convergence of comparative genomics, human population genetics, and mechanistic biology on the same two target families is what gives us confidence that these are worth the resource investment to advance. Any single one of those evidence streams is insufficient — comparative genomics alone generates too many candidates to pursue, and human GWAS hits alone have a poor record of translating to therapeutics. The overlap is where we have chosen to focus, and Klotho and FOXO3 are currently the strongest examples of that overlap in our prioritized target list.
